Total
0
Shares
Patrys (ASX:PAB) - - The Market Herald
Source: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Initial data from Patrys' (PAB) latest preclinical study find its PAT-DX1 candidate significantly reduces pancreatic tumour growths in animal models
  • PAT-DX1 reduced the growth of pancreatic tumours by 26 per cent and increased survival rates from 19 to 28 days, the data show
  • The study was conducted in the laboratory of Associate Professor Marina Pajic of the Garvan Institute of Medical Research
  • Patrys shares are up 2.04 per cent to trade at 5 cents at 1:17 pm AEST

Initial data from Patrys' (PAB) latest preclinical study have found its PAT-DX1 candidate significantly reduced pancreatic tumour growths in animal models.

The study found a twice-weekly treatment of PAT-DX1 reduced the growth of pancreatic tumours by 26 per cent and increased median survival by 47 per cent, from 19 days to 28 days.

Patrys said the nature of pancreatic cancer tumours made it makes it difficult to develop traditional antibody-based therapeutics for the disease and that its candidate could be a strong contender for future development of deoxymab-based therapies.

Patrys Chief Executive Officer and Managing Director, James Campbell said the findings validated the approach the company had taken with its antibody platform.

"We believe the combination of natural tumour targeting with blocking DNA damage repair, which Patrys’ deoxymabs offers, provides a unique and very powerful approach for tackling difficult-to-treat cancers," he said.

"On the back of this exciting data, we look forward to continuing our work with Associate Professor Pajic evaluating the potential of both PAT-DX1 and PAT-DX3 as new, potent treatments for pancreatic cancer."

The study was conducted in the laboratory of Associate Professor Marina Pajic of the Garvan Institute of Medical Research.

Patrys shares were up 2.04 per cent to trade at 5 cents at 12:06 pm AEST.

PAB by the numbers
More From The Market Herald
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon - The Market Herald

" ImpediMed (ASX:IPD) initiates SOZO heart failure program

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge - The Market Herald

" Invex Therapeutics (ASX:IXC) pens agreement for commercialisation of Presedin

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) subsidiary appoints US distributor

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett - The Market Herald

" Paradigm Biopharma (ASX:PAR) receives FDA feedback for knee osteoarthritis drug

Paradigm Biopharmaceuticals (PAR) has received feedback from US Food and Drug Administration (FDA) for its knee osteoarthritis drug.